The latest price target for Acer Therapeutics Inc (OTC:ACER) was reported by HC Wainwright & Co. on September 5, 2023. The analyst firm set a price target for $0.00 expecting ACER to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Acer Therapeutics Inc (OTC:ACER) was provided by HC Wainwright & Co., and Acer Therapeutics Inc downgraded their neutral rating.

There is no last upgrade for Acer Therapeutics Inc

The last downgrade for Acer Therapeutics Inc happened on September 5, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Acer Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acer Therapeutics Inc, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acer Therapeutics Inc was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.

While ratings are subjective and will change, the latest Acer Therapeutics Inc (ACER) rating was a downgraded with a price target of $0.00 to $0.00. The current price Acer Therapeutics Inc (ACER) is trading at is $0.66, which is out of the analyst’s predicted range.